REPAIR Impact Fund supports upsized MinervaX EUR 47.4m Series B financing to advance novel vaccine against Gr. B Streptococcus

Today the Novo Holdings REPAIR Impact Fund announces a further investment in MinervaX, a privately held Danish biotechnology company developing a novel vaccine against Group B Streptococcus (GBS), renewing its commitment to the company following two tranches of investment in 2018 and 2019.  Initial investment in MinervaX and has since been supported by the Novo Holdings REPAIR Impact Fund.  The new investment is part of an upsized EUR 47.4 Million series B financing round additionally supported by new investors, Sanofi Ventures, Wellington Partners, Adjuvant Capital, Industrifonden and existing investor Sunstone Life Science Ventures and LF Investment. Proceeds will advance the clinical development of MinervaX’s novel GBS vaccine through Phase II clinical trials, as well as manufacturing and regulatory preparation for Phase III.

Read more….

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...